Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression

Journal of Cellular Biochemistry

Volumn 84, Issue 1, 2002, Pages 188-200

  Taneja, Samir S ^a   Susan Ha, B S ^a   Garabedian, Michael J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

26S proteasome; Androgen; Cell cycle; Prostate cancer; Retinoblastoma protein; Ubiquitination

Indexed keywords

ANDROGEN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; MESSENGER RNA; METRIBOLONE; PROTEASOME; RETINOBLASTOMA PROTEIN; SERINE; UBIQUITIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STIMULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

EID: 0035192219     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.1278     Document Type: Article

References (65)

1. The recognition component of the N-end rule pathway
2. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
3. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models
4. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol
5. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
6. The cell cycle-regulating transcription factors E2F-RB
7. Androgen receptor mutants that affect normal growth and development
8. Androgen receptor: An overview
9. Hormonal therapy of prostatic carcinoma. Defining the challenge
10. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
11. Stromal-epithelial interactions in normal and abnormal prostatic development
12. Mesenchymal-epithelial interactions in the growth and development of the prostate
13. Endocrine therapy of advanced carcinoma of the prostate
14. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells
15. A cell-specific and selective effect on transactivation by the androgen receptor
16. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes
17. The role of RB in cell cycle control
18. Stromal-epithelial interactions in the normal and neoplastic prostate
19. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model
20. Translational control of p27Kip1 accumulation during the cell cycle
21. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1)
22. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas
23. Endocrine-induced regression of cancers
24. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
25. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
26. Proteolytic degradation of the retinoblastoma family protein p107: A putative cooperative role of calpain and proteasome
27. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization
28. Nuclear import of the human androgen receptor
29. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis
30. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones
31. 1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells
32. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest
33. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer
34. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
35. Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer
36. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
37. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2
38. Regulation of androgendependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes
39. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats
40. Allelic loss on chromosome 13q in human prostate carcinoma
41. Control of pRB phosphorylation
42. The retinoblastoma gene family: Cousins with overlapping interests
43. Viewpoint: Putting the cell cycle in order
44. Activation of the human androgen receptor through a protein kinase A signaling pathway
45. 1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
46. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration
47. Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants
48. Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation
49. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer
50. Cyclin E-CDK2 is a regulator of p27Kip1
51. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery
52. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
53. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
54. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
55. Androgen receptors in endocrine-therapy-resistant human prostate cancer
56. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
57. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids
58. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
59. 1 cyclins for degradation by the ubiquitin proteolytic pathway
60. SCF ubiquitin protein ligases and phosphorylation-dependent proteolysis
61. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
62. 1/S cyclin-dependent kinases
63. DUB-1, a deubiquitinating enzyme with growth-suppressing activity
64. DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes